Cancer Research's New Vanguard: Elite Scientists Join NCC's Funding Board

NEW YORK, NY – June 17, 2026 – The National Cancer Center (NCC), a non-profit with a 73-year history of fueling scientific discovery, has announced the appointment of two of the nation’s leading oncologists to its Scientific Advisory Board (SAB). Dr. Allison Betof-Warner of Stanford University and Dr. Rizwan Romee of Harvard Medical School and the Dana-Farber Cancer Institute will now help steer the organization’s mission to fund high-risk, high-reward early-stage cancer research. While on the surface a standard board appointment, this move represents a calculated reinforcement against a gathering storm: the precarious state of federal funding for life-saving science.

As members of the SAB, Drs. Betof-Warner and Romee will be instrumental in evaluating and awarding fellowships to promising young scientists. Their addition brings world-class expertise at a time when private philanthropy is becoming an increasingly critical lifeline for innovation.

Reinforcing the Front Lines of Innovation

The strategic value of these appointments lies in the specific, cutting-edge expertise each researcher brings. Their work represents the vanguard of modern oncology, focusing on harnessing the body's own immune system to fight cancer—a field that continues to yield revolutionary treatments.

Dr. Allison Betof-Warner is a formidable force in melanoma and solid tumor oncology. As the Director of the Melanoma Program and Solid Tumor Cellular Therapy at Stanford, her work centers on one of the most complex challenges in cancer treatment: resistance to immunotherapy. She is a principal investigator on clinical trials for patients with immunotherapy-refractory melanoma and has been a leader in advancing tumor-infiltrating lymphocyte (TIL) therapy, an innovative approach where a patient's own immune cells are harvested from their tumor, multiplied in a lab, and re-infused to attack the cancer. Her deep understanding of why current therapies fail is precisely the kind of forensic knowledge needed to identify research that can overcome these hurdles.

Dr. Rizwan Romee, an Associate Professor at Harvard and an oncologist at Dana-Farber, is a pioneer in the field of Natural Killer (NK) cell therapy. His lab focuses on the genetic manipulation of these potent immune cells to enhance their cancer-killing abilities. Using advanced tools like CRISPR, Dr. Romee's team is engineering NK cells to better navigate and survive the hostile tumor microenvironment, a major barrier to effective cell therapies. His discovery of "memory-like" NK cells, which show enhanced and persistent anti-leukemia activity, has already paved the way for new clinical protocols. His work represents a crucial next step in cellular immunotherapy, aiming to create more powerful and durable treatments for both blood cancers and solid tumors.

"Their rich expertise in medical oncology and passion for research to find causes and treatments for cancer will bring new energy and ideas to our cause," said NCC Scientific Advisory Board Chair Dr. Victoria Seewaldt. The combined acumen of these two leaders in immunotherapy and cellular therapy significantly enhances the NCC's ability to vet and champion projects with the potential for true paradigm shifts.

Navigating the "Valley of Death" in Cancer Research

The appointments come at a pivotal moment for the U.S. scientific community. The path from a promising lab discovery to a clinically available treatment is fraught with financial peril, a gap often called the "valley of death." This chasm is widening due to alarming trends in federal research funding. Recent reports indicate a severe contraction in financial support from the National Institutes of Health (NIH), with cancer research funding seeing a precipitous 31% drop in early 2025 compared to the previous year. Furthermore, the National Cancer Institute (NCI), the world's largest public funder of cancer research, faces a proposed budget cut of over 40% for the upcoming fiscal year.

These cuts create a chilling effect, disproportionately impacting early-career investigators and high-risk projects that don't yet have the extensive preliminary data required for large government grants. This is the critical gap that organizations like the National Cancer Center are built to fill. By providing seed funding—its fellowships offer $60,000 for a first year—the NCC empowers young scientists to pursue bold ideas that larger institutions might deem too preliminary.

Both new appointees explicitly acknowledged this vital role. "National Cancer Center fills a critical gap in cancer research by supporting promising early-stage research from young scientists," Dr. Betof-Warner stated. "I am excited to join the Scientific Advisory Board to support potentially exceptional but often underfunded research pathways that could lead to a cure."

Dr. Romee echoed this sentiment, emphasizing the NCC's unique position. "NCC has a proven track record of supporting bold, cutting-edge research that larger institutions might overlook," he said. "I am eager to leverage my background in cancer immunotherapy to help select and champion the most promising scientific projects."

A Global Strategy for a Global Foe

Cancer knows no borders, and neither does the research to defeat it. The National Cancer Center's strategy reflects this reality, fostering a global constellation of talent. This year alone, the organization awarded $426,000 to seven researchers—four new fellows and three renewals. This cohort is notably international, with awardees hailing from China, the Netherlands, and London, in addition to the United States, all working at premier American research institutions.

The projects funded are as diverse as their principal investigators, targeting everything from the metabolic pathways of liver cancer and the cellular mechanics of glioblastoma to novel therapeutic strategies for breast and prostate cancer. This international brain trust is essential for accelerating progress, as different perspectives and approaches converge on a common problem.

The addition of Drs. Betof-Warner and Romee, who operate at the pinnacle of globally recognized institutions, further strengthens this network. Their involvement not only brings top-tier evaluation to the fellowship selection process but also connects the NCC’s grantees to a wider ecosystem of elite science, potentially opening doors for future collaborations and larger-scale funding.

In a world where scientific progress is threatened by budget cuts and shifting priorities, the deliberate cultivation of talent is not just beneficial—it is essential for long-term security. By reinforcing its scientific leadership and continuing to invest in the next generation of international researchers, the National Cancer Center is placing a strategic bet on the most valuable asset in the fight against cancer: human ingenuity.